论文部分内容阅读
晚期卵巢癌以铂类为主的一线方案化疗后,近50％无临床发现但二探术证实存留肿瘤,其中3/4肉眼可见肿瘤>5cm。妇科肿瘤专家组(GOG)60号方案即为对Ⅲ、Ⅳ期上皮性卵巢癌亚理想手术后(残余肿瘤>1cm)分别采用CAP方案和BCG治疗的随机前瞻性试验。本研究对晚期卵巢癌一线方案化疗后临床完全有效和部分有效或疾病稳定者进行二次剖腹探查同时细胞减灭术。回顾GOG 153例病例记录并分析生存情况。
In the first-line regimen of platinum-based first-line chemotherapy for advanced ovarian cancer, nearly 50% had no clinical findings, but two probing tests confirmed the presence of tumors, of which 3/4 naked eyes had tumors >5 cm. The Gynecologic Oncology Group (GOG) No. 60 program is a randomized prospective trial using CAP regimen and BCG therapy after sub-optimal surgery for stage III and IV epithelial ovarian cancer (residual tumor >1 cm). In the present study, a second exploratory laparotomy and cytoreductive surgery was performed in patients with completely effective and partially effective or stable disease after first-line chemotherapy for advanced ovarian cancer. Review 153 cases of GOG records and analyze survival.